Two years ago data from the DESTINY-Breast04 trial, testing Enhertu in breast cancer patients with low HER2 expression, prompted a standing ovation from delegates at the American Society of Clinical Oncology annual meeting. At this year’s ASCO the product proved its worth in an earlier setting and in patients with even lower levels of the antigen, and this presentation too was greeted with applause. (Also see "ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm" - Scrip, 6 June, 2022.)
ASCO: Enhertu’s Empire Expands
“Transformative” data could move Daiichi Sankyo and AstraZeneca’s conjugate into ultralow HER2 expressers, and allow its use ahead of chemo in breast cancer.
More from ASCO
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.